Premium
PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA
Author(s) -
Frank M.,
Khodadoust M.,
Chu M.,
Kohrt H.,
Advani R.,
Alizadeh A.,
Reddy S.,
Maeda L.,
Gupta N.,
Laport G.,
Meyer E.,
Miklos D.,
Negrin R.,
Rezvani A.,
Weng W.,
Sheehan K.,
Czerwinski D.,
Faham M.,
Okada A.,
Moore H.,
Phillips D.,
Wapnir I.,
Brody J.,
Levy R.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_72
Subject(s) - medicine , leukapheresis , mantle cell lymphoma , autologous stem cell transplantation , vaccination , rash , minimal residual disease , adverse effect , peripheral blood mononuclear cell , oncology , gastroenterology , immunology , lymphoma , cd34 , bone marrow , stem cell , genetics , biology , biochemistry , chemistry , in vitro